Regional Citrate Anticoagulation Using a Calcium-containing Replacement Solution for Continuous Venovenous Hemofiltration

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10001042

Enrollment

Unknown

Registered

2010-09-15

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute/chronic renal failure

Interventions

A:CVVH with calcium-free replacement solution

B:CVVH with calcium-containing replacement solution

Total:CVVH with calcium-containing replacement solution

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: With the need of renal replacement therapy because of acute/chronic renal failureAcute renal failure (ARF): 1. ARF combined with hyperkalemia, acidosis, pneumonedema; 2. ARF combined with heart failure; 3. ARF combined with encephaledema; 4. ARF combined with high catabolism; 5. ARF combined with ARDS; 6. Hemodynamic instability; 7. After cardiosurgery; 8. SepsisChronic renal failure under maintenance hemodialysis: (1) acute pneumonedema; (2) Hemodynamic instability; (3) renal edema; (4) hydrothorax or ascites.

Exclusion criteria

Exclusion criteria: 1. Less than 18 years old; 2. Hypercalemia (serum total calcium > 2.6mmol/L); 3. Citrate acid can't be metabolized efficiently because of severe hyoxemia, hepatic renal failure and muscle hypoperfusion; 4. With the need of additional anticoagulant or hemostasis drug in the treatment; 5. HIV infection; 6. Pregnancy, organ transplantation recipient within 1 year or cachexia; 7. Allergy of cardiopulmonary circulation, anticoagulant or blood purification equipments; 8. Cannot undergo blood purification treatment because of other diseases or having severe complications during treatment; 9. Cannot cooperate effectively during treatment; 10. Involved in other clinical trails; 11. Considered not suitable for the trail by doctors (at least 2 attendings)

Design outcomes

Primary

Measure	Time frame
Concentration of the citrate (in peripheral blood);Acid-base parameters (PH,HCO3-,AG);APACHE score;Life time of the filter;Electrolyte (Ca2+,Na+,P-);Coagulation parameters(APTT,PT,PLT);Survival rate in 30d, 60d;Adverse reaction (bleeding , allergic reaction, et;ICU duration;Effect of blood purification (Cr, Bun);	—

Countries

China

Contacts

Public ContactPing Fu, Ling Zhang

fupinghx@163.com+86 18980601201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026